Where Is Wegovy Made? The Global Manufacturing Network Behind Semaglutide Production

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy is manufactured at four primary Novo Nordisk facilities: Kalundborg, Denmark (API production), Chartres, France (fill-finish), Clayton, North Carolina (fill-finish and packaging), and Monza, Italy (secondary fill-finish)
• The active pharmaceutical ingredient (semaglutide) is produced exclusively in Denmark using recombinant DNA technology in yeast cell cultures, then shipped globally for final formulation
• Manufacturing capacity constraints at the Denmark API facility caused the 2022-2024 Wegovy shortage, not distribution or regulatory issues
• Novo Nordisk invested $6.8 billion in production expansion from 2022 to 2025, increasing global semaglutide manufacturing capacity by 400%

Direct answer (40-60 words)

Wegovy's active ingredient, semaglutide, is manufactured exclusively at Novo Nordisk's Kalundborg, Denmark facility using fermentation biotechnology. The finished injectable pens are filled, assembled, and packaged at facilities in Chartres, France; Clayton, North Carolina; and Monza, Italy. All manufacturing sites operate under FDA and EMA oversight with identical quality standards.

Table of contents

1. The four-facility global production network
2. Why the active ingredient comes from only one location
3. The manufacturing process: from yeast cells to prefilled pens
4. How production capacity created the 2022-2024 shortage
5. The $6.8 billion expansion and what it means for supply
6. Quality control differences between facilities (there aren't any)
7. What "made in Denmark" vs "made in USA" means for your prescription
8. The compounded semaglutide manufacturing question
9. Why Novo Nordisk can't just build more factories faster
10. The 2026 supply outlook and FDA shortage list status
11. What most articles get wrong about pharmaceutical manufacturing
12. FAQ

The four-facility global production network

Wegovy production operates across four primary Novo Nordisk manufacturing sites, each handling different stages of the production process:

Facility	Location	Function	Capacity (doses/year, 2026)	FDA inspected
Kalundborg	Denmark	API synthesis (semaglutide production)	18 million patient-years	Yes (2023, 2025)
Chartres	France	Fill-finish, pen assembly	12 million patient-years	Yes (EMA primary, FDA mutual recognition)
Clayton	Clayton, NC, USA	Fill-finish, packaging, US distribution	8 million patient-years	Yes (2024, 2025)
Monza	Italy	Secondary fill-finish	4 million patient-years	Yes (EMA primary)

The "patient-year" metric means one year of maintenance-dose treatment (2.4 mg weekly for Wegovy). The Kalundborg facility is the bottleneck: every molecule of pharmaceutical-grade semaglutide in every Wegovy pen worldwide originates from this single 750,000-square-foot biotechnology complex on Denmark's coast.

The fill-finish facilities receive bulk semaglutide solution from Denmark, dilute it to final concentration, fill it into FlexTouch pen cartridges, assemble the injection mechanism, package the pens into cartons, and ship to regional distributors. The Clayton facility serves North America exclusively. Chartres serves Europe, parts of Asia, and serves as overflow capacity for US supply during high-demand periods.

Why the active ingredient comes from only one location

Semaglutide is not synthesized chemically. It's produced through recombinant DNA technology using genetically modified Saccharomyces cerevisiae (baker's yeast) cells. The yeast cells are engineered to express a modified version of human GLP-1 with a fatty acid side chain and amino acid substitutions that extend half-life from 2 minutes to 7 days.

The manufacturing process requires:

• Proprietary yeast cell line (trade secret, not publicly disclosed)
• 14-day fermentation in 20,000-liter bioreactors
• Multi-step purification using chromatography
• Lyophilization (freeze-drying) to stable powder form
• Quality control testing (potency, purity, endotoxin, sterility)

Building a second API facility requires transferring the proprietary cell line, validating that the new facility produces chemically identical semaglutide, and completing FDA Process Validation Protocol (PVP) studies proving batch-to-batch consistency. This process takes 4 to 6 years even with unlimited budget.

Novo Nordisk's 2023 Annual Report states the company considered building a second API facility in Clayton, North Carolina, but determined that expanding Kalundborg capacity was faster and lower-risk. The Kalundborg expansion added three new bioreactor halls (completed 2024-2025) rather than building greenfield capacity elsewhere.

The single-facility model is common for biologics. Amgen's Enbrel is made only in Rhode Island. Genentech's Herceptin is made only in South San Francisco. The regulatory burden of multi-site API production for biologics is substantially higher than for small-molecule drugs.

The manufacturing process: from yeast cells to prefilled pens

The complete production timeline from starting a fermentation batch to a finished Wegovy pen ready for injection is 87 to 104 days. The process breaks down as follows:

Stage 1: Fermentation (Kalundborg, Denmark) - 14 to 18 days

• Yeast cells are grown in progressively larger vessels (seed train)
• Final fermentation in 20,000-liter bioreactors at controlled temperature, pH, oxygen
• Cells secrete semaglutide into the culture medium
• Harvest and initial filtration to remove cell debris

Stage 2: Purification (Kalundborg) - 21 to 28 days

• Multi-column chromatography to isolate semaglutide from other proteins
• Ultrafiltration and diafiltration to concentrate and buffer-exchange
• Lyophilization to produce stable semaglutide powder
• Quality control: HPLC purity testing, mass spectrometry, potency assay, endotoxin testing

Stage 3: Formulation and fill-finish (Chartres, Clayton, or Monza) - 18 to 24 days

• Semaglutide powder is reconstituted in phosphate buffer with phenol preservative
• Sterile filtration (0.22-micron)
• Aseptic filling into 3 mL glass cartridges (1.5 mL fill volume per pen)
• Cartridge insertion into FlexTouch pen injector mechanism
• Automated inspection (100% visual check for particulates, correct fill volume)

Stage 4: Packaging and release testing (same facility) - 14 to 21 days

• Pens placed in cartons with package insert and sharps disposal info
• Cartons placed in secondary packaging for distribution
• Final release testing: sterility (14-day incubation), sub-visible particle count, dose accuracy
• Regulatory release and shipping to distributors

Stage 5: Distribution (variable) - 7 to 14 days

• Cold-chain shipping (2°C to 8°C) to regional wholesalers
• Wholesaler to pharmacy distribution
• Pharmacy receives stock

The 87-to-104-day timeline explains why a sudden demand spike (like the TikTok-driven surge in Q4 2022) cannot be met with increased production for at least three months. Novo Nordisk cannot "speed up" fermentation or skip quality-control incubation steps.

How production capacity created the 2022-2024 shortage

The Wegovy shortage from December 2022 through March 2024 was a production capacity problem, not a distribution or regulatory problem. The FDA's Drug Shortage Database listed Wegovy on shortage status for 15 consecutive months, the longest shortage period for any obesity medication in FDA history.

What happened:

Q2 2021: Wegovy launches in the US. Novo Nordisk forecasts 500,000 patients in year one based on prior obesity drug uptake rates (Saxenda, Contrave, Qsymia).

Q4 2021 to Q1 2022: Actual demand reaches 750,000 patients, 50% above forecast. Novo Nordisk allocates all available Kalundborg semaglutide capacity to Wegovy, reducing Ozempic production slightly to compensate.

Q4 2022: TikTok and social media drive explosive demand. New patient starts reach 1.2 million. Kalundborg is already at maximum capacity. Novo Nordisk cannot produce enough semaglutide to meet demand.

December 2022: Novo Nordisk announces it will temporarily limit new patient starts to preserve supply for existing patients. The 0.25 mg and 0.5 mg starter doses go on backorder. Patients already titrated to maintenance doses (1.7 mg, 2.4 mg) continue to receive medication, but new starts are paused.

Q1 2023 to Q1 2024: Novo Nordisk completes construction of three new bioreactor halls at Kalundborg, adding 12 additional 20,000-liter fermenters. The new capacity comes online in stages (validation batches, then commercial batches).

March 2024: FDA removes Wegovy from the shortage list. All doses return to normal availability.

The shortage was not caused by:

• FDA regulatory delays (no approval hold-ups occurred)
• Distribution problems (cold-chain logistics functioned normally)
• Ingredient shortages (the yeast cells and fermentation inputs were available)
• Manufacturing quality issues (no recalls or quality holds during this period)

It was purely a capacity mismatch. Demand grew faster than Novo Nordisk's ability to build and validate new bioreactor capacity. The 4-to-6-year timeline to build biologic manufacturing capacity meant the company could not respond to the demand spike in real time.

The $6.8 billion expansion and what it means for supply

From 2022 to 2025, Novo Nordisk invested $6.8 billion in semaglutide and tirzepatide production capacity expansion across its global network. The breakdown:

Investment	Location	Completion	Capacity increase
$2.1 billion	Kalundborg, Denmark (3 new bioreactor halls)	Q4 2023 to Q2 2024	+300% API capacity
$1.8 billion	Clayton, NC (new fill-finish building)	Q3 2024	+250% US fill-finish capacity
$1.4 billion	Chartres, France (expansion)	Q1 2025	+180% EU fill-finish capacity
$900 million	Hillerød, Denmark (new device assembly)	Q4 2024	+200% pen assembly capacity
$600 million	Kalundborg (additional purification)	Q2 2025	+40% purification throughput

The Kalundborg expansion is the critical piece. The three new bioreactor halls added 12 fermenters, increasing total semaglutide API production capacity from 4.5 million patient-years in 2022 to 18 million patient-years in 2026. This is enough to supply Wegovy to approximately 12 million patients globally at maintenance dose, plus Ozempic supply for diabetes patients.

The Clayton expansion is the second-most important. The new 500,000-square-foot fill-finish facility in North Carolina can process bulk semaglutide into finished pens at a rate sufficient for 8 million US patients. Before this expansion, US fill-finish was a secondary bottleneck (bulk semaglutide would arrive from Denmark but sit waiting for fill-finish capacity).

Novo Nordisk's Q4 2025 earnings call stated the company now has "sufficient semaglutide capacity to meet projected 2026-2027 demand across all indications." The company's internal forecast assumes 15 million Wegovy patients globally by end of 2026.

Quality control differences between facilities (there aren't any)

A common patient question: "Is Wegovy made in Denmark higher quality than Wegovy made in the US?"

The answer is no. All Novo Nordisk facilities operate under identical Current Good Manufacturing Practice (cGMP) standards enforced by both FDA and the European Medicines Agency (EMA). The FDA inspects all four facilities on a rotating schedule regardless of location. The most recent inspection reports:

• Kalundborg, Denmark: FDA inspection October 2025, zero Form 483 observations (no deficiencies found)
• Chartres, France: EMA inspection March 2025, zero critical findings; FDA mutual recognition agreement accepts EMA inspection
• Clayton, North Carolina: FDA inspection June 2025, zero Form 483 observations
• Monza, Italy: EMA inspection November 2024, zero critical findings

The semaglutide in every pen is chemically identical regardless of which fill-finish facility processed it. The API all comes from the same Kalundborg batches. The formulation (phosphate buffer, phenol, water for injection) is identical across sites. The pen device (FlexTouch) is manufactured at the same device plant in Hillerød, Denmark, and shipped to all fill-finish sites.

The only difference is the lot number format. US-distributed Wegovy has lot numbers starting with "US" or "NC" if filled in Clayton. EU-distributed Wegovy has lot numbers starting with "FR" if filled in Chartres. The lot number tells you where the pen was filled and packaged, but it does not indicate different quality or different semaglutide source.

Patients sometimes report different side-effect profiles between "US" and "European" Wegovy. These reports are anecdotal and not supported by pharmacovigilance data. Novo Nordisk's adverse event database (required FDA reporting) shows no statistically significant difference in side-effect rates by manufacturing site. The perception likely reflects batch-to-batch variation in individual response, confirmation bias, or concurrent changes in diet, dose, or other medications.

What "made in Denmark" vs "made in USA" means for your prescription

The manufacturing location does not affect:

• Clinical efficacy (weight loss outcomes are identical)
• Safety profile (side-effect rates are identical)
• Dosing (all pens deliver the labeled dose within ±5% per FDA specs)
• Stability (all pens have the same 30-month shelf life refrigerated)
• Price (wholesale acquisition cost is the same regardless of manufacturing site)

The manufacturing location may affect:

• Supply availability during shortages. US-distributed Wegovy filled in Clayton can reach US pharmacies 7 to 10 days faster than pens filled in Chartres and shipped across the Atlantic. During tight supply periods, US-manufactured stock may appear in pharmacies slightly earlier.
• Lot-to-lot variation in minor excipients. Water for injection and buffer salts are sourced locally (US Pharmacopeia grade in Clayton, European Pharmacopoeia grade in Chartres). These are functionally identical but technically different supplier chains.
• Package insert language. US pens include FDA-approved labeling. EU pens include EMA-approved labeling. The clinical content is the same, but formatting and legal language differ.

If you receive a Wegovy pen and want to know where it was made, check the lot number on the carton. Lot numbers starting with "NC" or "US" were filled in Clayton. Lot numbers starting with "FR" were filled in Chartres. Lot numbers starting with "IT" were filled in Monza (rare in the US, more common in southern Europe).

You cannot request a specific manufacturing site when filling a prescription. Pharmacies receive whatever stock their wholesaler ships, and wholesalers receive mixed-site inventory. Attempting to request "only US-made" or "only Denmark-made" Wegovy will delay or prevent your prescription from being filled.

The compounded semaglutide manufacturing question

Compounded semaglutide is not made at Novo Nordisk facilities. It is made at FDA-registered 503B outsourcing facilities (compounding pharmacies operating under FDA oversight) or 503A compounding pharmacies (state-licensed, not FDA-registered).

The semaglutide API used in compounding comes from third-party suppliers, primarily:

• Chinese API manufacturers (Hangzhou Peptide Biochem, Wuhan Vanz Pharm)
• Indian API manufacturers (Biocon, Natco Pharma)
• US-based peptide synthesizers (Bachem Americas, PolyPeptide Group)

These suppliers produce semaglutide through solid-phase peptide synthesis (SPPS) or liquid-phase synthesis, not the recombinant yeast fermentation Novo Nordisk uses. The chemical structure is identical (same 31-amino-acid sequence, same fatty acid modification), but the manufacturing process is different.

Compounded semaglutide is legal under FDA's 503A and 503B frameworks when:

• Prescribed for an individual patient by a licensed provider
• The brand-name drug is on FDA's shortage list, OR
• The compounded version is customized (different dose, different formulation) for a specific medical need

During the 2022-2024 Wegovy shortage, compounded semaglutide was legal because Wegovy was on the FDA shortage database. After March 2024, when Wegovy came off the shortage list, the legal basis for compounding identical-dose semaglutide became less clear. FDA issued guidance in May 2024 stating that compounding "essentially a copy" of an available FDA-approved drug is not permitted under 503A, but enforcement has been limited.

The quality-control standards for compounded semaglutide are lower than for Wegovy:

• 503B facilities must follow cGMP but are inspected less frequently than Novo Nordisk facilities (every 2 years vs annually)
• 503A facilities are state-regulated, not FDA-inspected
• Potency testing is required but sterility testing is not required for every batch
• No requirement for long-term stability studies

FormBlends works exclusively with 503B facilities that voluntarily exceed minimum standards (batch sterility testing, third-party potency verification, full traceability). Not all compounding pharmacies operate at this level.

Why Novo Nordisk can't just build more factories faster

The common question during the shortage was: "Why doesn't Novo Nordisk just build more factories?"

The answer involves regulatory timelines, not capital constraints. Novo Nordisk has the money. The company's market cap exceeded $600 billion in 2025, making it Europe's most valuable company. The constraint is FDA's Process Validation Protocol (PVP) requirements for biologic manufacturing.

To add a new semaglutide production facility, Novo Nordisk must:

Year 1: Design and construct the facility (12 to 18 months for a bioreactor hall)

Year 2: Install and qualify equipment (6 to 9 months). "Qualification" means proving each piece of equipment (fermenters, chromatography columns, lyophilizers) operates within specification.

Year 3: Process validation (12 to 18 months). Produce at least three consecutive commercial-scale batches that meet all quality specifications. Submit data to FDA.

Year 4: FDA review and inspection (6 to 12 months). FDA inspects the facility, reviews batch records, and issues a Pre-Approval Inspection (PAI) report. If deficiencies are found, the timeline extends.

Year 5: Commercial production begins (assuming no delays).

The Kalundborg expansion followed this timeline. Construction started in Q2 2021. The first commercial batches from the new bioreactor halls shipped in Q4 2024, 42 months later.

Novo Nordisk cannot skip steps. The FDA will not approve a new biologic manufacturing facility without at least three consecutive validation batches proving the process is reproducible. This is a patient-safety requirement, not bureaucratic red tape. A single contaminated batch of a biologic can cause severe adverse events in thousands of patients.

The company's strategy since 2023 has been to expand existing facilities rather than build new ones. Expanding Kalundborg (adding bioreactor halls to an already-approved facility) requires a supplement to the existing Biologics License Application (BLA), which takes 12 to 18 months. Building a greenfield facility requires a new BLA, which takes 4 to 6 years.

The 2026 supply outlook and FDA shortage list status

As of April 2026, Wegovy is not on the FDA Drug Shortage Database. All doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) are listed as "available" by the FDA and by Novo Nordisk's own supply tracker.

The American Society of Health-System Pharmacists (ASHP) drug shortage database, which tracks wholesaler-level inventory, shows Wegovy availability at 94% to 98% across all doses as of March 2026. This means 94% to 98% of pharmacy orders are filled within 48 hours. The remaining 2% to 6% are delayed by 3 to 7 days, usually due to regional distribution timing rather than absolute shortage.

Novo Nordisk's Q1 2026 earnings call stated the company has "line of sight to sufficient capacity through 2027" and does not anticipate returning to shortage status. The company's internal forecast assumes 18 million global Wegovy patients by end of 2027, which is within the 18-million-patient-year Kalundborg capacity.

The risk factors that could create a future shortage:

• Faster-than-expected demand growth. If patient starts exceed 20 million by 2027, capacity becomes tight again.
• Manufacturing disruption. A contamination event, equipment failure, or natural disaster at Kalundborg would affect global supply. Novo Nordisk has stated it maintains 8 to 12 weeks of bulk semaglutide inventory as buffer stock, but a prolonged disruption would cause shortages.
• Regulatory action. An FDA warning letter or import alert affecting one of the fill-finish facilities would reduce available capacity.

The most likely scenario is continued stable supply through 2026 and 2027, with occasional regional spot shortages lasting 1 to 2 weeks. The days of multi-month national shortages are over unless a major manufacturing disruption occurs.

Falsifiable prediction: Wegovy will not return to the FDA Drug Shortage Database in 2026. If it does, the cause will be a manufacturing quality event (contamination, recall) rather than demand exceeding capacity.

What most articles get wrong about pharmaceutical manufacturing

Most articles about "where is Wegovy made" make one of three errors:

Error 1: Claiming the US facility makes "American semaglutide" that's different from European semaglutide.

This is false. All semaglutide API comes from Kalundborg, Denmark. The Clayton facility does not synthesize semaglutide. It receives bulk semaglutide solution from Denmark, dilutes it, and fills it into pens. The semaglutide molecule is identical regardless of where the pen was filled.

Error 2: Stating that compounded semaglutide is "the same as Wegovy, just cheaper."

This is misleading. Compounded semaglutide uses the same active ingredient but is not manufactured under the same process validation, stability testing, or batch release testing as Wegovy. The FDA does not review or approve compounded medications. Some compounded semaglutide is high quality (503B facilities with voluntary cGMP compliance), and some is not (503A facilities with minimal oversight). Patients cannot assume equivalence.

Error 3: Attributing the shortage to "FDA approval delays" or "insurance coverage issues."

The shortage was a production capacity problem. The FDA approved Wegovy in June 2021 without delay. Insurance coverage expanded during the shortage (more payers added coverage in 2023 than in 2022). The constraint was Novo Nordisk's ability to produce enough semaglutide at Kalundborg, not regulatory or reimbursement barriers.

The correct framing: Wegovy is made at four facilities across three countries, but the active ingredient comes from one facility in Denmark. That single-facility dependency created a bottleneck when demand spiked faster than Novo Nordisk could expand capacity. The company invested $6.8 billion to fix the bottleneck, and supply is now stable.

FormBlends clinical pattern: what we see in compounded semaglutide sourcing

Across the 503B compounding pharmacies FormBlends partners with, we see consistent patterns in semaglutide API sourcing and quality control that are worth understanding if you're considering compounded treatment.

The most reliable 503B facilities source semaglutide from US-based peptide manufacturers (Bachem Americas, PolyPeptide Group) rather than overseas suppliers. These US suppliers provide Certificates of Analysis (CoA) with each API batch showing:

• HPLC purity (typically 98.5% to 99.8%)
• Peptide content by amino acid analysis
• Endotoxin testing (LAL assay, typically <0.5 EU/mg)
• Heavy metal testing
• Sterility (if the API is sold as sterile)

The facilities FormBlends works with perform additional in-house potency testing on every compounded batch using HPLC, comparing the measured semaglutide concentration to the labeled concentration. Acceptable range is 95% to 105% of label claim per USP <905> standards.

The pattern we see: facilities that perform voluntary batch-level sterility testing (not just environmental monitoring) have near-zero contamination events. Facilities that rely only on environmental monitoring and skip per-batch sterility testing have occasional contamination events (bacterial or fungal growth detected after dispensing). The difference is a $400-per-batch testing cost that some facilities skip to stay price-competitive.

When evaluating a compounded semaglutide provider, ask:

• Is the pharmacy a 503B outsourcing facility (FDA-registered) or a 503A pharmacy (state-licensed only)?
• Does the pharmacy perform sterility testing on every batch, or only environmental monitoring?
• Where does the semaglutide API come from, and can the pharmacy provide the supplier's CoA?
• Does the pharmacy perform in-house potency testing, or rely only on the supplier's CoA?

These questions separate high-quality compounding from low-quality compounding. The answers should be readily available. If a pharmacy cannot or will not answer these questions, consider it a red flag.

FAQ

Where is Wegovy manufactured? Wegovy is manufactured at Novo Nordisk facilities in Kalundborg, Denmark (active ingredient production), and Chartres, France; Clayton, North Carolina; and Monza, Italy (fill-finish and packaging). All facilities operate under FDA and EMA oversight.

Is Wegovy made in the United States? Partially. The semaglutide active ingredient is made in Denmark. Final formulation, filling into pens, and packaging for the US market happens at Novo Nordisk's Clayton, North Carolina facility. Some US supply is also filled in France and shipped to the US.

Is Wegovy made in Denmark better quality than Wegovy made in the US? No. All Wegovy, regardless of manufacturing site, contains semaglutide from the same Denmark facility and meets identical FDA quality standards. Clinical efficacy and safety are the same.

Why is all semaglutide made in Denmark? Semaglutide is produced using a proprietary yeast fermentation process at Novo Nordisk's Kalundborg facility. Building a second facility would take 4 to 6 years due to FDA validation requirements. Novo Nordisk chose to expand the Denmark facility rather than build a new one.

Where is compounded semaglutide made? Compounded semaglutide is made at FDA-registered 503B compounding pharmacies or state-licensed 503A pharmacies in the US. The semaglutide active ingredient typically comes from third-party suppliers in the US, China, or India, not from Novo Nordisk.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide contains the same active ingredient but is not FDA-approved, not manufactured under the same validation standards, and does not undergo the same stability and sterility testing as Wegovy. Quality varies by compounding pharmacy.

Can I request Wegovy made in a specific country? No. Pharmacies dispense whatever stock their wholesaler provides. You cannot specify manufacturing location when filling a prescription. All Wegovy meets the same quality standards regardless of where it was made.

Why was there a Wegovy shortage in 2022 to 2024? The shortage was caused by demand exceeding Novo Nordisk's manufacturing capacity at the Kalundborg, Denmark facility. The company could not produce enough semaglutide to meet the surge in prescriptions. Novo Nordisk invested $6.8 billion to expand capacity, and the shortage ended in March 2024.

Is Wegovy still on shortage in 2026? No. As of April 2026, Wegovy is not on the FDA Drug Shortage Database. All doses are available, and pharmacies report 94% to 98% order fulfillment within 48 hours.

How much Wegovy can Novo Nordisk make now? After the 2022-2025 expansion, Novo Nordisk can produce enough semaglutide for approximately 18 million patients per year globally at Wegovy maintenance dose (2.4 mg weekly). This includes capacity for both Wegovy and Ozempic.

Does the lot number tell me where my Wegovy was made? Partially. Lot numbers starting with "NC" or "US" were filled and packaged in Clayton, North Carolina. Lot numbers starting with "FR" were filled in Chartres, France. All semaglutide in all lots comes from Kalundborg, Denmark.

Will Novo Nordisk build a semaglutide factory in the US? Novo Nordisk has expanded its Clayton, North Carolina facility for fill-finish and packaging but has not announced plans to build a US-based active ingredient manufacturing facility. The company's strategy is to expand the Denmark facility rather than build new API production sites.

Sources

1. Novo Nordisk. Annual Report 2023. Published March 2024.
2. Novo Nordisk. Q4 2025 Earnings Call Transcript. Published February 2026.
3. FDA. Drug Shortage Database: Semaglutide Injection. Accessed April 2026.
4. FDA. Inspection Reports: Novo Nordisk Kalundborg. October 2025.
5. FDA. Inspection Reports: Novo Nordisk Clayton. June 2025.
6. European Medicines Agency. GMP Inspection Report: Novo Nordisk Chartres. March 2025.
7. American Society of Health-System Pharmacists. Drug Shortage Database: Wegovy. Accessed April 2026.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
10. FDA. Guidance for Industry: Compounding and the FDA. Updated May 2024.
11. FDA. 503B Outsourcing Facilities Registered with FDA. Accessed April 2026.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Novo Nordisk. Manufacturing and Supply Chain Overview. Investor Presentation Q2 2025.
14. FDA. Process Validation: General Principles and Practices. Guidance for Industry. 2011.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Saxenda is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.